Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cantourage Group (HIGH) Fair Value & Analysis

Healthcare · DE · Market cap €78.3M

Price€6.30
Fair Value€11.78
Upside+87.0%
Quality79/100
Evidence: Low Range €8.83 – €14.72

Fair value as of: Jun 24, 2026

Analysis

Cantourage Group (HIGH) currently trades at €6.30, while our model-based Fair Value estimate is €11.78 — implying the stock looks roughly 87.0% undervalued today. We read business quality at 79/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Cantourage Group SE operates as a medical cannabis company in Europe and internationally. The company offers cannabis flowers, extracts, dronabinol, tetrahydrocannabinol, and cannabidiol products. It exports its products. The company distributes its products through pharmacies, wholesalers, and partners. Cantourage Group SE was founded in 2019 and is headquartered in Berlin, Germany.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Cantourage Group (HIGH) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €11.78 versus a price of €6.30 — about +87% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HIGH?
Our 21-model fair value for Cantourage Group is €11.78 (as of Jun 24, 2026), built from audited fundamentals. The current price is €6.30.
What is the quality score of HIGH?
Cantourage Group has a Quality Score of 79/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.